Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)
China
· Delayed Price · Currency is CNY 8.93
-0.11 (-1.22%)
At close: Mar 9, 2026
SHA:600867 Revenue
Tonghua Dongbao Pharmaceutical had revenue of 806.10M CNY in the quarter ending September 30, 2025, with 13.90% growth. This brings the company's revenue in the last twelve months to 2.74B, up 12.74% year-over-year. In the year 2024, Tonghua Dongbao Pharmaceutical had annual revenue of 2.01B, down -34.66%.
Revenue (ttm)
2.74B
Revenue Growth
+12.74%
P/S Ratio
6.33
Revenue / Employee
803.92K
Employees
3,410
Market Cap
17.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.01B | -1.07B | -34.66% |
| Dec 31, 2023 | 3.08B | 296.96M | 10.69% |
| Dec 31, 2022 | 2.78B | -489.44M | -14.98% |
| Dec 31, 2021 | 3.27B | 375.73M | 12.99% |
| Dec 31, 2020 | 2.89B | 115.02M | 4.14% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shandong Buchang Pharmaceuticals | 10.96B |
| Zhejiang Medicine | 8.96B |
| Fujian Cosunter Pharmaceutical | 430.98M |
| Betta Pharmaceuticals | 3.26B |
| Walvax Biotechnology | 2.40B |
| China Resources Double-Crane Pharmaceutical | 10.95B |
| Shenzhen Kangtai Biological Products | 2.70B |
| Nanjing King-Friend Biochemical Pharmaceutical | 3.76B |